Patients' preferences for adjuvant endocrine therapy in early breast cancer: what makes it worthwhile?

Br J Cancer · 2005 · PMC2361537 · PMID 16333242

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a weak trendno p-value reported

There was a weak trend towards larger gains being judged necessary if the endocrine therapy was being recommended to a sister or best friend (median gain of 10 vs 5% on a baseline of 80% 5 year survival without adjuvant endocrine therapy, P =0.07).

also in 1,404 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.